GSKGlaxoSmithKlineRunning, no new patients
All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
Multiple Myeloma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 21 (final count)
- Started
- Feb 10, 2022
- Main results expected
- May 27, 2024
- Fully finished
- Jun 25, 2029
- Results posted
- Jun 11, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-Free Survival (PFS)
Measured over: Up to approximately 120 weeks
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06956170 · record last updated 2026-06-12 · checked 2026-11-09 15:47 UTC